What the main weight study found
For adults without diabetes in STEP 1, average weight loss over 68 weeks was 14.9% on semaglutide; the dummy-injection group lost 2.4%.
Participants had obesity or overweight with a weight-related condition; both groups received support with food and activity.
The study report in the New England Journal of Medicine ↗The study was funded by the maker and provided both lifestyle support and regular visits.
Those figures are group averages, and individual results vary.
What happened after treatment ended
In a smaller STEP 1 follow-up group, about two-thirds of the earlier weight loss returned during the year after semaglutide was stopped.
The follow-up report in Diabetes, Obesity and Metabolism ↗This is a reason to discuss the plan beyond the first prescription. It does not decide how long any particular person will receive treatment.
Questions that put results in context
Ask whether a headline is about weight, blood sugar or another outcome. Then ask whether the people studied resemble the people the service plans to treat.
- Which product and form did the study use?
- What other support did people receive?
- What happened in the comparison group?
- What did the study leave unanswered?
A clear explanation can include uncertainty. Ask for the limits in ordinary words before deciding what the result means for your care.